Latest news with #AheadofWallStreet
Yahoo
4 days ago
- Business
- Yahoo
Top Analyst Reports for Mastercard, Verizon & Stryker
Thursday, June 5, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc. (MA), Verizon Communications Inc. (VZ) and Stryker Corp. (SYK), as well as two micro-cap stocks Espey Mfg. & Electronics Corp. (ESP) and Comstock Holding Companies, Inc. (CHCI). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the research reports have been hand-picked from the roughly 70 reports published by our analyst team can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each can read today's AWS here >>> Trump, Xi Speak; Jobless Claims, Productivity & Deficit Reports OutToday's Featured Research ReportsMastercard's shares have outperformed the Zacks Financial Transaction Services industry over the past year (+31% vs. +27.8%). The company's acquisitions are helping the company to grow addressable markets and drive new revenue streams. Mastercard expects mid-teens net revenue growth in 2Q25. The accelerated adoption of digital and contactless solutions is providing an opportunity for its business to expedite its shift to digital. Strong cash flows support its growth initiatives and enable shareholder value-boosting efforts through repurchases and dividends. MA repurchased shares worth $2.5 billion in 1Q25. Operating cash flows surged 42.3% YoY in the first quarter of 2025. However, MA's dividend yield is lower than the industry average. The Zacks analyst expects adjusted operating expenses to grow 14.8% year over year in 2025. High rebates and incentives may weigh on net revenues. As such, the stock warrants a cautious stance.(You can read the full research report on Mastercard here >>>)Shares of Verizon have outperformed the Zacks Wireless National industry over the past six months (+5.5% vs. +4.9%). The company is witnessing significant 5G adoption and fixed wireless broadband momentum. Its reliable, plug-and-play Internet connectivity, desk phone and security solutions with 24/7 tech support are driving the digital transformation of small business mmWave footprint delivers game-changing experiences for the densest parts of the network and offers highly predictable signal waves, leading to greater efficiency and less interference for customers. The acquisition of Frontier Communications accelerates broadband expansion. However, the spectrum crunch has become a major issue in the U.S. telecom industry. Most of the carriers are finding it increasingly difficult to manage surging data traffic. High spending on promotional activities to attract customers is straining profit. Weakness in the wireline business is a concern.(You can read the full research report on Verizon here >>>)Stryker's shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+6.5% vs. +5.8%). The company is poised for growth, driven by rising demand for robotic-assisted procedures, hospital capital expenditures and international expansion. The Mako SmartRobotics platform fuels adoption, while acquisitions like Inari Medical and Vertos Medical enhance the portfolio. Stryker is actively integrating new technologies such as AI-driven imaging and smart surgical systems to improve patient outcomes and maintain its competitive edge. Pricing improvements and a strong hospital order book support growth in rest of 2025. However, foreign exchange volatility and acquisition-related margin pressures may impact earnings. Supply chain disruptions and rising costs could strain profitability. Intensifying competition in robotics and MedTech demands constant innovation. Macroeconomic risks, including potential downturns in healthcare spending and regulatory shifts, add uncertainty.(You can read the full research report on Stryker here >>>)Shares of Espey have outperformed the Zacks Electronics - Military industry over the year-to-date period (+33.5% vs. -3.5%). This microcap company with market capitalization of $112.89 million posted strong YTD FY25 results, with revenue up 26.7% to $34.4 million, driven by defense power supply programs and improved gross margins. Its record $138 million backlog — anchored by long-term contracts and key customer relationships — provides multi-year revenue visibility, with nearly half scheduled beyond FY26. Strategic wins include $49.3 million in multi-year contracts for the U.S. Navy's Columbia-class submarines, supporting long-term positioning in electrification systems. A debt-free balance sheet, $28.3M in liquidity, and $10.8M in federal funding for capacity upgrades enhance strategic flexibility and throughput. Espey benefits from defense modernization tailwinds, especially in naval and airborne electrification. However, risks include persistent margin headwinds from early-stage programs, fixed cost pressures, and high customer concentration. (You can read the full research report on Espey here >>>)Comstock's shares have outperformed the Zacks Building Products - Home Builders industry over the year-to-date period (+22% vs. -11.4%). This microcap company with market capitalization of $99.01 million benefits from stable, recurring revenue from asset management agreements extending through 2035, featuring cost-plus structures and performance incentives. Comstock's debt-free, asset-light model enhances financial flexibility, while consistent revenue growth — 18.8% YoY in Q1 2025 — and expanding profitability demonstrate strong operational leverage. The company manages a high-quality, transit-oriented portfolio poised to scale to 10 million SF, with a defined development pipeline supporting future revenue growth. Strong tenant demand, long lease terms, and strategic alignment with urbanization further reinforce its defensible cash flows. However, risks include revenue concentration with a related party, low third-party diversification, and deferred incentive fee recognition. Regulatory headwinds and heavy geographic concentration in the D.C. metro area pose additional exposure. (You can read the full research report on Comstock here >>>)Other noteworthy reports we are featuring today include Louisiana-Pacific Corp. (LPX), Emerson Electric Co. (EMR) and Simon Property Group, Inc. (SPG).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Mastercard's (MA) Accretive Buyouts Aid, Elevated Costs Hurt Verizon (VZ) Rides on Robust Demand for Fixed Wireless Services Diversified Product Portfolio Drives Stryker's (SYK) Prospects Featured Reports Intelligent Devices Unit Aids Emerson (EMR), High Debt AilsPer the Zacks analyst, Emerson's Intelligent Devices unit is driven by strength in the final control and measurement & analytical businesses. High debt level remains concerning for the company. Retail Recovery Aid Simon (SPG) Despite Online Growth Trend Per the Zacks Analyst, solid retail demand, focus on supporting omnichannel retailing and developing mixed-use assets bode well for Simon, despite e-commerce adoption and high interest rates Dupixent Profits Fuels Regeneron (REGN), Eylea Decline A WoePer the Zacks analyst, stellar performance of Dupixent fuels Regeneron even as lead drug Eylea faces challenges. The company's progress with the oncology portfolio is also impressive. High Rates to Aid Truist Financial (TFC), Asset Quality WeakPer the Zacks analyst, relatively higher rates, business restructuring, fee income, and solid balance sheet will support Truist Financial's financials. Yet, high costs and weak asset quality are woes. Cardinal Health's (CAH) Diverse Products Gives Competitive EdgePer the Zacks analyst, Cardinal Health's diversified portfolio represents long-term opportunities. Its products provide the company with a competitive edge in the niche space with fierce competition. V.F. Corp's (VFC) Reinvent Transformation Plan Bodes WellPer the Zacks analyst, V.F. Corp's Reinvent transformation program, aimed at reducing costs, strengthening balance sheet, revitalizing U.S. business, and driving Vans turnaround, is progressing well. Solid Air Traffic Aids AAR Corp (AIR), Supply Chain Woes Per the Zacks analyst, steadily growing air passenger traffic is boosting AAR Corp.'s Parts Supply business. Yet persistent supply chain challenges plaguing the aerospace sector remains a concern. New Upgrades Siding Business Aids Louisiana-Pacific (LPX), High Costs AilPer the Zacks analyst, Louisiana-Pacific is gaining from strength in the Siding business and disciplined capital management. However, the weak OSB market and high costs are hurting prospects. Juniper (JNPR) Rides on Healthy Demand & Product InnovationPer the Zacks analyst, strong demand in the Cloud and Enterprise verticals combined with the development of cutting-edge AI native networking solutions will likely drive Juniper's top line. Solid Demand for AI Servers Aids Dell Technologies (DELL)Per the Zacks analyst, Dell is benefiting from strong demand for AI servers driven by ongoing digital transformation and heightened interest in generative AI applications. New Downgrades High Debt and Extreme Oil Price Volatility Ail Matador (MTDR)Per the Zacks analyst, Matador Resources faces elevated financial risk due to its high debt levels. Its exposure to volatility in crude prices may negatively impact its profitability. High Labor Costs & Debt Dent Alaska Air's (ALK) ProspectsThe Zacks analyst is concerned that high labor costs are limiting Alaska Air's bottom-line growth. High debt load represents another concern. Weak Demand in End Markets to Hurt International Paper (IP)The Zacks analyst is concerned that the ongoing weak demand in both the Packaging Solutions North America and Packaging Solutions EMEA segments will continue to impact International Paper's results. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mastercard Incorporated (MA) : Free Stock Analysis Report Simon Property Group, Inc. (SPG) : Free Stock Analysis Report Verizon Communications Inc. (VZ) : Free Stock Analysis Report Emerson Electric Co. (EMR) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report Louisiana-Pacific Corporation (LPX) : Free Stock Analysis Report Espey Mfg. & Electronics Corp. (ESP) : Free Stock Analysis Report Comstock Holding Companies, Inc. (CHCI): Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
30-05-2025
- Business
- Yahoo
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands
Chicago, IL – May 30, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. ABBV, Intuitive Surgical, Inc. ISRG, Hamilton Beach Brands Holding Co. HBB and AXIL Brands, Inc. AXIL. The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., AbbVie Inc. and Intuitive Surgical, Inc., as well as two micro-cap stocks Hamilton Beach Brands Holding Co. and AXIL Brands, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Markets Stay Green After Tariff Ruling, Jobless Claims, Q1 GDP Today's Featured Research Reports Shares of Berkshire Hathaway have gained +10.8% over the year-to-date period against the Zacks Insurance - Property and Casualty industry's gain of +16.1%. The company is one of the largest property and casualty insurance companies, with numerous diverse business activities. A strong cash position supports earnings-accretive bolt-on buyouts and is indicative of its financial flexibility. Continued insurance business growth fuels an increase in float, drives earnings and generates maximum return on equity. The non-insurance businesses have also been doing well in the last few years. The insurer has also started increasing its investment in Japan. A sturdy capital level provides further impetus. However, exposure to cat loss induces earnings volatility and also affects underwriting results. Huge capital expenditure remains a headwind. Also, it remains to be seen how the behemoth fares when Greg Abel succeeds Warren Buffett as CEO of Berkshire. (You can read the full research report on Berkshire Hathaway here >>>) AbbVie's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+6.1% vs. -4.2%). The company beats first-quarter estimates for both earnings and sales. AbbVie has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and should support top-line growth in the next few years. AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. It expects to return to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE. However, the company faces several near-term headwinds like Humira LOE impact, increasing competitive pressure on Imbruvica and slowing sales of its aesthetics franchise. (You can read the full research report on AbbVie here >>>) Shares of Intuitive Surgical have outperformed the Zacks Medical - Instruments industry over the year-to-date period (+6.9% vs. -9.2%). The company ended the first quarter on a strong note, beating estimates on both counts. Revenues are likely to be driven by continued improvement in the company's da Vinci procedure volume, coupled with strong Ion procedure growth. ISRG topline is also likely aided by rising pricing of procedures to fight inflationary pressure. Launch of da Vinci SP in Europe and da Vinci 5 in U.S. market are bringing additional system placements. Opening new manufacturing facilities in Germany and Bulgaria should boost supply. However, the continued slowdown in bariatric procedures is likely to continue in 2025 amid the rise of GLP-1 medications, hurting top-line growth. ISRG also expects a slow, gradual decline in Instruments & Accessories revenues per procedure over the next few years due to growth in benign procedures. Operating expenses are likely to be on the higher side in 2025. (You can read the full research report on Intuitive Surgical here >>>) Hamilton Beach Brands' shares have outperformed the Zacks Household Appliances industry over the year-to-date period (+13.6% vs. -27.7%). This microcap company with market capitalization of $253.29 million posted strong first-quarter 2025 results, with gross margin up 120 bps to 24.6% despite tariff headwinds, driven by favorable mix and pricing. Operating profit rebounded to $2.3 million amid tight cost control. Tariff mitigation, sourcing shifts, and foreign trade zone certification support margin resilience. The high-margin HealthBeacon unit is scaling rapidly, with 50%+ patient growth expected in 2025, aided by a new OptumHealth launch. Premium products like CHI and the upcoming Lotus line support share gains in the $4 billion U.S. appliance market. E-commerce now accounts for 40% of U.S. sales, driven by a strong digital strategy. Geographic and channel diversification, including growth in Mexico and a new Sunkist partnership, enhances stability. Solid liquidity and disciplined capital allocation reinforce long-term growth prospects. (You can read the full research report on Hamilton Beach Brands here >>>) Shares of AXIL Brands have outperformed the Zacks Consumer Products - Staples industry over the year-to-date period (+60.4% vs. +3.2%). This microcap company with market capitalization of $41.03 million offers a compelling growth narrative driven by strong direct-to-consumer momentum, supported by enhanced e-commerce, data-driven marketing, and favorable Cyber Monday timing. Gross margins remained robust at 71.7% in the third quarter of fiscal 2025 due to operational efficiency and product mix, with adjusted EBITDA margin expanding to 12.9%. Improved liquidity ($4.77 million in cash) and positive operating cash flow ($1.7 million for the first nine months of fiscal 2025) enhance financial flexibility. Strategic United States supply chain shifts bolster resilience, while global direct-to-consumer-led expansion reduces domestic dependency. However, risks persist: weak inventory turnover, vendor and receivables concentration, elevated selling, general, and administrative expenses, and uncertain execution of domestic manufacturing could pressure margins and limit scalability if growth lags. (You can read the full research report on AXIL Brands here >>>) Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Hamilton Beach Brands Holding Company (HBB) : Free Stock Analysis Report AXIL Brands, Inc. (AXIL): Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Top Stock Reports for Coca-Cola, Abbott & AT&T
Tuesday, May 27, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Co. (KO), Abbott Laboratories (ABT) and AT&T Inc. (T). These research reports have been hand-picked from the roughly 70 reports published by our analyst team can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each can read today's AWS here >>> Pre-Markets Up on New Tariff DevelopmentsToday's Featured Research ReportsCoca-Cola's shares have outperformed the Zacks Beverages - Soft drinks industry over the year-to-date period (+16% vs. +8%). The company delivered a strong first-quarter 2025, marking its ninth consecutive quarter of beating top- and bottom-line expectations. First-quarter 2025 performance was driven by broad-based growth, improved price/mix, and effective execution of its all-weather strategy, which blends marketing, innovation, and revenue growth management. Innovation and marketing continue to drive brand momentum, with impactful campaigns and product launches. However, volume softness in key markets like North America and Mexico, due to weather, timing shifts, and weaker sentiment, tempered momentum. Currency headwinds, higher taxes, and rising interest costs continue to be concerns. Despite reaffirming its 2025 guidance, management signaled a cautious near-term outlook, describing Q2 as potentially "choppy."(You can read the full research report on Coca-Cola here >>>)Shares of Abbott have outperformed the Zacks Medical - Products industry over the year-to-date period (+15.7% vs. +4.3%). The company's pipeline is unlocking new growth opportunities, supporting the company's positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company's next-generation suite of systems, is a key driver in the core lab diagnostics business. Abbott is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. Within Nutrition, despite softness in its international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business. Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott's Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also adds to the worry. (You can read the full research report on Abbott here >>>)AT&T's shares have outperformed the Zacks Wireless National industry over the year-to-date period (+23% vs. +13.5%). The company is witnessing healthy momentum in its postpaid wireless business with a lower churn rate and increased adoption of higher-tier unlimited plans. AT&T expects to gain a competitive edge over rivals through edge computing services that allow businesses to route application-specific traffic where they need it and where it's most effective. Acquisition of Lumen's fiber internet connectivity business will significantly expand market reach. Collaboration with Ericsson to deploy a commercial-scale open radio access network will likely bring long term benefits. However, the company is facing a steady decline in linear TV subscribers and legacy services. Stiff competition in the U.S. wireless market remains a major concern. As AT&T tries to woo customers with discounts, freebies and cash credits, margin pressures tend to rise.(You can read the full research report on AT&T here >>>)Other noteworthy reports we are featuring today include Honda Motor Co., Ltd. (HMC), Vale S.A. (VALE) and Centene Corporation (CNC).Director of ResearchSheraz MianNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Coca-Cola's (KO) All-Weather Strategy to Boost the Top Line Strength in Diabetes Care Aids Abbott (ABT), FX Woes Stay AT&T (T) Rides on Healthy Demand, Strategic Acquisition Featured Reports Surge in Hybrid Adoption Aids Honda (HMC), Rising Capex AilsPer the Zacks analyst, the surge in hybrid adoption is boosting Honda's sales. However, rising capex requirements are likely to hurt the company's cash flows. Investments, Cost Cuts Aid Vale (VALE) Amid Price VolatilityPer the Zacks analyst, investment in growth projects, focus on improving quality and productivity and lowering costs will fuel Vale's growth in the backdrop of volatile iron ore prices. Strategic Acquisitions and High Premiums Aid Centene (CNC)Per the Zacks analyst, strategic buyouts are expanding Centene's markets and membership. Additionally, rising commercial premiums are boosting revenue. Corpay (CPAY) Grows Organically, High Interest Expense AilPer the Zacks analyst, Corpay's organic growth is fueled by rise in volume and revenues per transaction in its payment programs. Rising interest expense affects bottom-line. Robust Growth in Payment Solutions Drives Jack Henry (JKHY)Per the Zacks Analyst, Jack Henry is benefiting from strength in its card processing solutions, driven by expanding transaction volumes. High Rates Aid East West Bancorp (EWBC), Asset Quality AilsPer the Zacks analyst, decent loan demand, relatively high rates and diverse fee income streams will aid East West Bancorp's revenues, while weak asset quality and subdued mortgage business are woes. Halozyme's (HALO) ENHANZE Drug Delivery Technology Aid GrowthPer the Zacks Analyst, Halozyme's collaboration deals with large pharma companies related to ENHANZE technology, drives revenues growth. Over dependence on partners for revenues remains a concern. New Upgrades Focus on Regulated Energy Delivery Aids MDU Resources (MDU)Per the Zacks analyst, MDU Resources benefits from its focus on regulated energy delivery business. Its investment of $3.06 billion through 2029 should improve the reliability of its services. EverQuote (EVER) Boasts Revenue Growth, Solid Balance SheetPer the Zacks analyst, consumer traffic, quote request volume and innovative advertiser products and services drive EverQuote revenues. Its strong balance sheet enables it to fulfill debt obligations. Product Launch & Expansion Efforts Aid JAKKS Pacific (JAKK)Per the Zacks analyst, JAKKS Pacific benefits from solid consumer demand for licensed toys and core product lines. Also, focus on FOB business model and retail expansion efforts bode well. New Downgrades USA Compression (USAC) Faces Flat Horsepower GrowthThe Zacks analyst warns that USA Compression's near-term outlook is modest, as horsepower growth lags forecasts and 2025 gains rely heavily on pricing rather than volume expansion. High Operating Costs are likely to hurt Abercrombie's (ANF) MarginPer the Zacks analyst, Abercrombie is reeling under rising operating expenses and elevated freight rates. It expects higher operating and freight costs to hurt margins in the first-half of fiscal 2025 High Costs, Stiff Competition Ail Evercore's (EVR) GrowthPer the Zacks analyst, high costs will impede Evercore's bottom-line growth while volatility of institutional AUM will hurt revenues. Stiff competition creates pricing and competitive pressures. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AT&T Inc. (T) : Free Stock Analysis Report CocaCola Company (The) (KO) : Free Stock Analysis Report VALE S.A. (VALE) : Free Stock Analysis Report Honda Motor Co., Ltd. (HMC) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
Chicago, IL – May 23, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, GE Aerospace GE and Amgen Inc. AMGN. Here are highlights from Thursday's Analyst Blog: The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., GE Aerospace and Amgen Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Markets Even Out as Investors Digest Tax Bill Shares of Eli Lilly have declined -10.9% over the past year versus the Zacks Large Cap Pharmaceuticals industry's decline of -14.7%. The company's Q1 earnings missed estimates while sales beat. Demand for popular GLP-1 drugs Mounjaro and Zepbound remains strong, making them the company's key top-line drivers. Though sales were below expectations in the second half of 2024, they picked up in the first quarter, driven by launches of the drugs in new international markets, and improved supply from ramped-up production. In the past two years, Lilly received approvals for some new drugs like Kisunla, Omvoh and Jaypirca, which are also contributing to its top-line growth. Lilly is also making rapid pipeline progress in obesity and diabetes. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. (You can read the full research report on Eli Lilly here >>>) GE Aerospace's shares have outperformed the Zacks Aerospace - Defense industry over the past year (+41.3% vs. +12.9%). The company has been witnessing strength in its businesses, driven by robust demand for commercial engines, propulsion and additive technologies. Rising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for the company. Portfolio-reshaping actions are likely to unlock values for its shareholders. The company raised its dividend by 28.6% to 36 cents per share in February 2025. For 2025, GE Aerospace expects organic revenues to grow in the low-double-digit range from the year-ago level. However, it has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect margins and profitability. Also, foreign exchange headwinds might be a concern for the company. (You can read the full research report on GE Aerospace here >>>) Shares of Amgen have declined -8.7% over the past year against the Zacks Medical - Biomedical and Genetics industry's decline of -16.1%. The company beat first-quarter estimates for both earnings and sales. Key medicines like Evenity, Repatha and Blincyto -- as well as newer medicines like Tavneos and Tezspire -- are driving sales, more than offsetting declining revenues from oncology biosimilars and legacy established products like Enbrel. New biosimilar launches are expected to contribute to top-line growth. Amgen also has some key pipeline assets in obesity and inflammation. However, increased pricing headwinds and competitive pressure are hurting sales of many products. Weakness in some key brands like Otezla and Lumakras create potential revenue headwinds. Sales of best-selling drugs Prolia and Xgeva are expected to decline from the second half of 2025 due to biosimilar competition. (You can read the full research report on Amgen here >>>) Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GE Aerospace (GE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Top Analyst Reports for Oracle, IBM & Merck
Wednesday, May 14, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Earth Science Tech, Inc. (ETST). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the research reports have been hand-picked from the roughly 70 reports published by our analyst team can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each can read today's AWS here >>> No Econ Reports Equals Good News in Pre-MarketToday's Featured Research ReportsOracle's shares have outperformed the Zacks Computer - Software industry over the past year (+39.2% vs. +10%). The company is gaining from the ongoing momentum across its cloud business, driven by the strong uptake of Oracle Cloud Infrastructure and Autonomous Database offerings, including from winning cloud-computing contracts from AI-focused solid adoption of cloud-based applications, comprising NetSuite Enterprise Resource Planning (ERP) and Fusion ERP, bodes well. ORCL's partnership with Amazon for Oracle Database@AWS and general availability of Oracle Database@Google holds promise. Oracle's Gen 2 Cloud is driving artificial intelligence clientele. Its share buybacks and dividend policy are Zacks analyst expects fiscal 2025 net sales to grow 7.7% from fiscal 2024. However, higher spending on product enhancements toward the cloud platform amid increasing competition in the cloud domain is likely to limit margin expansion.(You can read the full research report on Oracle here >>>)Shares of IBM have outperformed the Zacks Computer - Integrated Systems industry over the past year (+61.5% vs. -2.5%). The company is poised to benefit from strong demand for hybrid cloud and AI, driving growth in Software and Consulting. The company's growth is expected to be driven primarily by analytics, cloud computing, and security in the long core technology platform for AI capabilities watsonx is gaining significant market traction across industries. The company is collaborating with SAP to tap generative AI technology within the retail industry. The collaboration is likely to facilitate higher productivity and help accelerate business transformation in consumer-packaged goods and retail stiff competition in various end markets is straining profits. Stringent cost-cutting efforts to boost margins beyond a certain threshold are likely to impact product quality. IBM's frequent acquisitions have escalated integration risks.(You can read the full research report on IBM here >>>)Merck's shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (-26% vs. -4.7%). The company's rising competitive pressure on the diabetes franchise and persistent challenges for Gardasil in China remain overhangs. There are concerns about Merck's ability to successfully navigate the Keytruda loss of exclusivity period and potential competition for the Merck's first-quarter earnings and sales beat estimates. Its blockbuster drug, Keytruda, and new products have been driving sales. With continued label expansion into new indications, particularly earlier-stage launches, Keytruda is expected to see continued health is also contributing to growth. Merck boasts a strong cancer pipeline, including Keytruda, which should drive long-term growth. Merck is investing in M&A activity to strengthen its pipeline.(You can read the full research report on Merck here >>>)Shares of Earth Science Tech have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+11.4% vs. -7.8%). This microcap company with market capitalization of $42.53 million posted a 311.6% year-over-year revenue surge to $24.4 million for the nine months ended Dec. 31, 2024, driven by RxCompound and Peaks. The vertically integrated model, new revenue from shipping and balanced customer mix support cash flow rose to $2.4 million, reflecting tighter working capital controls. Gross margin held firm at 72.7% despite a 1,151% spike in salaries. Strategic acquisitions expanded pharmacy and telehealth capabilities, but integration, liquidity ($0.5 million cash against $2.3 million liabilities), and revenue concentration risks buybacks amid short-term debt, opaque marketing ROI, and thin net margins (8.5%) raise sustainability questions. Execution and financial discipline will be critical to support ongoing growth. The P/B ratio signals premium pricing based on asset expectations.(You can read the full research report on Earth Science Tech here >>>)Other noteworthy reports we are featuring today include CVS Health Corporation (CVS), MetLife, Inc. (MET) and Coinbase Global, Inc. (COIN).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Oracle (ORCL) Gains from Cloud Suite Adoption & Partnerships IBM Rides on Strong Customer Growth in Software Segment Keytruda Drives Merck (MRK) Sales Amid Gardasil China Issues Featured Reports Healthcare Delivery Aids CVS Health (CVS), Macro Woes StayThe Zacks analyst is impressed with solid revenue gains in CVS Health's Healthcare Delivery business, led by robust patient growth at Oak Street. Yet, shifting macroeconomy may hurt its operations. Acquisitions & Cost-Cutting Initiatives Aid MetLife (MET)Per the Zacks analyst, several acquisitions and partnerships will continue to bolster the capabilities and global presence of MetLife. Efforts to control costs should drive its margins. Coinbase (COIN) Banks on Improving Top Line, Expenses HurtPer the Zacks analyst, higher transaction revenues, subscription and services revenues, growth in crypto assets should drive Coinbase revenues. However, escalating expenses hurt its margins. Yum! Brands (YUM) Banks on Digital Efforts, High Costs HurtPer the Zacks analyst, Yum! Brands is likely to from digital efforts, increased kiosk adoption and unit expansion efforts. However, high costs and macro woes ail. Loan Growth Supports M&T Bank (MTB), Rising Costs a WoePer the Zacks analyst, M&T Bank's increasing loans and deposit balances are supporting its financials. Yet, investments in strengthening its franchise will keep expenses elevated. Wabtec (WAB) Benefits From Segmental Strength Amid Rising ExpensesPer the Zacks Analyst, Wabtec's top line is benefitting from higher sales across its Freight and Transit segments. Rising expenses pose a threat to the company's bottom line. Antero Resources (AR) to Gain from Vast Appalachia AssetsPer the Zacks analyst, Antero Resources is poised for growth with a strong foothold in the Appalachian Basin, backed by extensive premium drilling locations in Marcellus and Utica Shales. New Upgrades Steady Tower Demand Aids Crown Castle (CCI), Debt Burden AilPer the Zacks Analyst, Crown Castle's efforts to augment tower business bode well amid the rising wireless connectivity usage. Yet, customer concentration and high interest expenses ail. Seagate (STX) Rides on Mass Capacity Demand Amid High DebtPer the Zacks analyst, Seagate's performance is gaining from improving demand for mass capacity storage solutions and expansion into the SSD storage market. However, high indebtedness is a concern. Increasing Solar Projects Drive Emeren (SOL) Amid Supply Chain IssuesPer the Zacks analyst, Emeren is likely to benefit from its expanding solar projects worldwide. Yet supply chain issues result in delays and increase costs. New Downgrades Challenges in RV Market & Rising Expenses to Ail Thor (THO)Per the Zacks analyst, the anticipated challenges in the RV market are likely to hurt Thor's top-line growth. Rising SG&A expenses are likely to exert pressure on profit margins. Weakness in PTI Sector to Hurt MRC Global Amid Forex WoesPer the Zacks analyst, MRC Global is struggling with poor performance of the Production & Transmission Infrastructure sector due to completion of large projects. Forex woes are an added concern. Target (TGT) Struggles as Shoppers Cut Back on SpendingPer the Zacks analyst, Target's fourth quarter shows troubling signs with a decline in average transaction size, highlighting deepening consumer cutbacks. The average transaction amount fell 0.6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report International Business Machines Corporation (IBM) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report MetLife, Inc. (MET) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Oracle Corporation (ORCL) : Free Stock Analysis Report Earth Science Tech, Inc. (ETST) : Free Stock Analysis Report Coinbase Global, Inc. (COIN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
